Precision oncology: current and future platforms for treatment selection.

Tang, Xinran; Berger, Michael F; Solit, David B

Tang, Xinran; Berger, Michael F; Solit, David B.

Afiliación

Tang X; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA; Graduate School of Medical Sciences, Weill Cornell Medicine, New York, NY 10065, USA.
Berger MF; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA; Marie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA; Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Solit DB; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA; Marie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA. Electronic address: solitd@mskcc.org.

Trends Cancer ; 10(9): 781-791, 2024 Sep.

Article en En | MEDLINE | ID: mdl-39030146

ABSTRACT

ABSTRACT

Genomic profiling of hundreds of cancer-associated genes is now a component of routine cancer care. DNA sequencing can identify mutations, mutational signatures, and structural alterations predictive of therapy response and assess for heritable cancer risk, but it has been less useful for identifying predictive biomarkers of sensitivity to cytotoxic chemotherapies, antibody drug conjugates, and immunotherapies. The clinical adoption of molecular profiling platforms such as RNA sequencing better suited to identifying those patients most likely to respond to immunotherapies and drug combinations will be critical to expanding the benefits of precision oncology. This review discusses the potential advantages of innovative molecular and functional profiling platforms designed to replace or complement targeted DNA sequencing and the major hurdles to their clinical adoption.

Asunto(s)

Biomarcadores de Tumor; Neoplasias; Medicina de Precisión; Humanos; Medicina de Precisión/métodos; Medicina de Precisión/tendencias; Neoplasias/genética; Neoplasias/terapia; Neoplasias/tratamiento farmacológico; Biomarcadores de Tumor/genética; Oncología Médica/tendencias; Oncología Médica/métodos; Terapia Molecular Dirigida/métodos; Terapia Molecular Dirigida/tendencias; Inmunoterapia/métodos; Inmunoterapia/tendencias; Mutación; Secuenciación de Nucleótidos de Alto Rendimiento/métodos; Genómica/métodos

Palabras clave

DNA sequencing; RNA sequencing; cell free DNA; functional precision oncology; targeted cancer therapy

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Biomarcadores de Tumor / Medicina de Precisión / Neoplasias Límite: Humans Idioma: En Revista: Trends Cancer Año: 2024 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Estados Unidos

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google